|
CCNY expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.4266035281737E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.33230004595708E-09 |
| Normal-vs-Stage2 |
1.84859999996512E-06 |
| Normal-vs-Stage3 |
2.51499998604743E-09 |
| Normal-vs-Stage4 |
8.38140001846455E-10 |
| Stage1-vs-Stage2 |
6.253200E-01 |
| Stage1-vs-Stage3 |
2.665200E-01 |
| Stage1-vs-Stage4 |
4.412000E-02 |
| Stage2-vs-Stage3 |
7.633200E-01 |
| Stage2-vs-Stage4 |
2.261200E-01 |
| Stage3-vs-Stage4 |
2.730400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.94969612571572E-11 |
| Normal-vs-AfricanAmerican |
1.081750E-03 |
| Normal-vs-Asian |
4.2983000000385E-06 |
| Caucasian-vs-AfricanAmerican |
4.058600E-01 |
| Caucasian-vs-Asian |
8.282800E-01 |
| AfricanAmerican-vs-Asian |
5.816000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.18950002572882E-09 |
| Normal-vs-Female |
2.31670016503926E-10 |
| Male-vs-Female |
4.563600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.59569999991227E-07 |
| Normal-vs-Age(41-60Yrs) |
7.97039989564041E-10 |
| Normal-vs-Age(61-80Yrs) |
8.3918982873854E-11 |
| Normal-vs-Age(81-100Yrs) |
5.038800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.097200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.790300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.475000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.744800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.831600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.895200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.736200E-01 |
| Classical-VS-Follicular |
1.665580E-02 |
| Classical-VS-Other |
2.721600E-01 |
| Classical-VS-Normal |
8.59299997824081E-09 |
| Tall-VS-Follicular |
2.683400E-01 |
| Tall-VS-Other |
3.364600E-01 |
| Tall-VS-Normal |
8.26810000000844E-05 |
| Follicular-VS-Other |
8.066600E-01 |
| Follicular-VS-Normal |
4.28379998140827E-09 |
| Other-VS-Normal |
2.721600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.27280458079349E-11 |
| Normal-vs-N1 |
2.70529999513158E-08 |
| N0-vs-N1 |
3.604600E-01 |
|
|
